ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents With Fragile X Syndrome: Role of Methylation Status as a Correlate to Disease Severity and as a Prognostic Biomarker

Elizabeth Berry-Kravis,[1] Craig Erickson,[2] Randi Hagerman,[3] Nicole Tartaglia,[4] Jonathan Cohen,[5] Terri Sebree,[6] Donna Gutterman,[6] Nancy Tich,[6] Thomas Dobbins,[7] Joseph M. Palumbo[6]

[1]Rush University Medical Center, Chicago, IL, USA; [2]Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; [3]University of California Davis Medical Center, Department of Pediatrics and MIND Institute, Sacramento, CA, USA; [4]Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA; [5]Fragile X Alliance, North Caulfield, VIC, Australia; [6]Zynerba Pharmaceuticals, Devon, PA, USA; [7]Dobbins Statistical Consulting, Blue Bell, PA, USA

BACKGROUND

- ZYN002 is a pharmaceutically manufactured transdermal cannabidiol (CDB) gel in development for the treatment of behavioral symptoms in Fragile X syndrome (FXS)
- CONNECT-FX is a randomized, double-blind, multinational, 14-week pivotal study to evaluate the efficacy and safety of ZYN002 in children/adolescents aged 3 through 17 years with a full *FMR1* gene mutation (**Figure 1**)
  - ZYN002 did not statistically significantly separate from placebo on the primary or key secondary endpoints in the full analysis set
- Building on current scientific evidence, a pre-planned ad hoc analysis of patients having at least 90% methylation ("full methylation" or FMet) of the impacted *FMR1* gene[a] was performed
  - The results suggest that ZYN002 may have benefit in patients with full methylation of the *FMR1* gene

OBJECTIVE

- To describe the results of the CONNECT-FX (ZYN2-CL-016) study in children/adolescents with FXS with full methylation of their *FMR1* gene

METHODS

- Patients were randomized to 12-weeks of ZYN002 (250 mg or 500 mg daily [weight-based]) or placebo, as add-on to standard of care
- The primary endpoint was change in the Social Avoidance subscale of the Aberrant Behavior Checklist–Community FXS (ABC–C_{FXS})
- Key secondary endpoints
  - Change from baseline to end of the treatment in
    - ABC-C_{FXS} Irritability subscale score
    - ABC-C_{FXS} Socially Unresponsive/Lethargic subscale score
  - Improvement in Clinical Global Impression (CGI-I) at end of treatment, anchored to FXS behaviors
- Safety assessments included adverse events, laboratory tests, and electrocardiograms in the full study population
- Efficacy results are reported for the FMet group

Figure 1. CONNECT-FX Study Design



*2-week placebo period followed by 12 weeks of treatment.

[a]*FMR1* methylation status was determined by using Southern blot analysis.

RESULTS

BASELINE DEMOGRAPHICS

- The FMet group represented 80% of the total study population
- Baseline characteristics of the FMet group are shown in **Table 1**

Table 1. Baseline Demographics, FMet Group

	Placebo	ZYN002	Total
n	77	92	169
Age (years)	9.6	9.2	9.4
Sex – Males	54 (70%)	65 (71%)	119 (70%)
Weight (kg)			
Median	33.9	35.7	35.0
Range (Min, Max)	15.6, 104.7	14.6, 87.0	14.6, 104.7
>35 kg, %	46%	53%	50%
Baseline psychoactive medications,* %	65%	54%	59%

*Did not include sleep medications.

EFFICACY RESULTS

- The FMet group achieved statistically significant improvement in the primary endpoint of ABC-C_{FXS} Social Avoidance at Week 12 (*P*=0.020, **Table 2 and Figure 2**)

Table 2. CONNECT-FX Results: FMet Group

		Placebo N=76			ZYN002 N=91				
	Endpoints	Baseline Mean (SE)	Week 12 Mean (SE)	Week 12 Median Percent Change	Baseline Mean (SE)	Week 12 Mean (SE)	Week 12 Median Percent Change	Treatment Difference / Odds Ratio†	Treatment *p*-value
Primary Endpoint	Social Avoidance	7.18 (0.32)	5.41 (0.42)	−21.1	7.12 (0.29)	4.32 (0.33)	−40.0	−1.00	**0.020***
Secondary Endpoints	Irritability	28.0 (1.56)	24.11 (1.56)	−11.6	29.36 (1.37)	22.69 (1.42)	−24.3	−2.30	0.091
	Socially Unresponsive /Lethargic	13.17 (0.85)	10.29 (0.80)	−20.5	13.30 (0.68)	9.03 (0.67)	−30.8	−1.17	0.135
	CGI-I	-	35.7%		-	51.1%		1.88†	0.056

*Statistically significant.

Figure 2. ABC-C_{FXS} Social Avoidance: FMet Group



Data represent observed cases: 4 patients did not have Week-12 ABC-C_{FXS} assessment.

- Clinically meaningful within-subject change was determined by psychometric analyses
- Significantly more ZYN002-treated FMet patients had a meaningful change in ABC-C_{FXS} subscales for Social Avoidance and Irritability (*P*=0.031 and *P*=0.036, respectively) (**Figure 3**)
- The number needed to treat (NNT) for Social Avoidance was 5.7 (Cohen's d of 0.52)

Figure 3. Greater Percentages of Participants Achieved Meaningful Change in ABC-C_{FXS} Social Avoidance and Irritability With ZYN002 vs Placebo



NNT=number needed to treat; OR= odds ratio
*Statistically significant, LS means.

- The FMet group achieved statistically significant improvements in Caregiver Global Impression-Change in Social Avoidance and Isolation, Irritable and Disruptive Behaviors, and Social Interactions (*P*=0.038, *P*=0.028, and *P*=0.002) (**Figure 4**)

Figure 4. Caregiver Global Impression-Change: FMet Group



*Statistically significant; *P*-values indicate "betterment" on ZYN002 vs "betterment" on placebo.

SAFETY RESULTS

- ZYN002 was very well tolerated in CONNECT-FX
- There were no serious or severe adverse events reported during the study
- All treatment-emergent adverse events (TEAEs) (any event, whether unrelated or related to study drug) were mild or moderate
  - The most common treatment-related TEAE was application site pain (ZYN002: 6.4%; placebo: 1.0%)
- Laboratory values for chemistry and hematology were comparable between the placebo and ZYN002 treatment groups, and there were no clinically relevant abnormalities in either group
  - There were no clinically significant changes to liver function tests

CONCLUSIONS

- To our knowledge, CONNECT-FX is the largest controlled study ever performed in FXS
- ZYN002 was well tolerated
- In the FMet group, ZYN002 was superior to placebo in multiple analyses
  1. Statistically significant mean change in Social Avoidance vs placebo
  2. Proportion of patients attaining threshold of clinically meaningful change in Social Avoidance and Irritability
  3. Caregiver reported improvements including Social Avoidance, Social Interaction, and Irritable behaviors
- Zynerba will be meeting with the FDA in Q4 2020
- These results may represent an important step forward in biomarker-driven prediction of response in FXS and neuroscience

ACKNOWLEDGEMENTS

Editorial/medical writing support under the guidance of the authors was provided by *p*-value communications, and was funded by Zynerba Pharmaceuticals, Devon, PA, USA, in accordance with Good Publication Practice (GPP3) guidelines (*Ann Intern Med.* 2015;163:461-464).

Disclosures: TS, DG, N Tich, and JP are employees of Zynerba Pharmaceuticals. TD is a contractor for Zynerba Pharmaceuticals. EBK, CE, RH, N Tartaglia, and JC have received research support from Zynerba Pharmaceuticals. The study was funded by Zynerba Pharmaceuticals.

Presented at the 2020 Child Neurology Society (CNS) – International Child Neurology Association (ICNA) Meeting; October 2020.